Browsing by Author "Freitas, A. R. R."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- 313P Disease and treatment patterns for advanced cholangiocarcinoma: A multicentric study from PortugalPublication . Gonçalves, J. C. N.; Freitas, A. R. R.; Fortuna, A. R.; Menezes, M. B.; Gramaça, J.; Fernandes, I. C. Gomes; Ângelo, I. C.; Trabulo, C. F. P.; Sousa, C. Xavier de; Pina, I. M. MatosGemcitabine plus cisplatin (GC) was standard first-line treatment for advanced biliary tract cancers until recently, supported by the UK ABC-02 study. However, TOPAZ-1 showed survival improvement with Durvalumab plus GC. Nevertheless, a significant proportion of patients face challenges with GC tolerability, prompting into alternatives such as gemcitabine and carboplatin (GCb). Moreover, there remains a paucity of stratified data pertaining to cholangiocarcinomas (CCA). We analyzed 5-year trends to determine treatment rates and cisplatin use in the real world.
- Disease and treatment patterns for advanced cholangiocarcinoma: A multicentric study from PortugalPublication . Gonçalves, J. C. N.; Freitas, A. R. R.; Fortuna, A. R.; Menezes, M. B.; Gramaça, J.; Fernandes, I. C. Gomes; Angelo, I. C.; Trabulo, C. F. P.; Sousa, C. Xavier de; Pina, I. M. MatosMeeting Gastrointestinal Cancers Congress of the European-Society-for-Medical-Oncology (ESMO) Background: Gemcitabine plus cisplatin (GC) was standard first-line treatment for advanced biliary tract cancers until recently, supported by the UK ABC-02 study. However, TOPAZ-1 showed survival improvement with Durvalumab plus GC. Nevertheless, a significant proportion of patients face challenges with GC tolerability, prompting into alternatives such as gemcitabine and carboplatin (GCb). Moreover, there remains a paucity of stratified data pertaining to cholangiocarcinomas (CCA). We analyzed 5-year trends to determine treatment rates and cisplatin use in the real world.